An endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors.
Three main kinds of ERAs exist:
- Dual ET Receptor Antagonists, which affect both endothelin A (ETA) and B receptors (ETB)
- Selective ETA Receptor Antagonists, which affect endothelin A receptors
- Selective ETB Receptor Antagonists, which affect endothelin B receptors
Macitentan, ambrisentan and bosentan are mainly used for the treatment of pulmonary arterial hypertension, while atrasentan is an experimental anti-cancer drug.
References
Medications used in the management of pulmonary arterial hypertension (B01, C02) | |
---|---|
Prostacyclin analogues | |
Endothelin receptor antagonists | |
PDE5 inhibitors | |
sGC stimulators | |
Adjunctive therapy |
Sympatholytic (and closely related) antihypertensives (C02) | |||||
---|---|---|---|---|---|
Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
Other antagonists |
| ||||
|
This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it. |